文献速递创伤与烧伤

创伤后氨甲环酸的研究优先方向:国家创伤研究行动计划二次分析

Research priorities in tranexamic acid after trauma: Secondary analysis of the National Trauma Research Action Plan.
PubMed 文献 · J Trauma Acute Care Surg · 2024-05-01
一句话结论国家创伤研究行动计划(NTRAP)专家小组德尔菲法共识别73个氨甲环酸相关问题,其中46个达成共识,归纳为21个优先研究问题。

该研究为NTRAP 11个专题小组德尔菲法共识研究问题的二次分析,通过关键词「tranexamic」和「TXA」检索数据库。7个小组共提出73个氨甲环酸相关问题,46个达成共识;涉及最多的主题为结局(64%)、适应证(49%)和特定患者人群(38%)。因跨小组重叠,问题经归纳排序后形成21个优先研究问题;作者认为这些关键主题应在未来创伤氨甲环酸研究的资助中优先考虑。

要点

  • NTRAP 11个专题小组中7个小组共提出73个氨甲环酸相关问题,46个达成共识。
  • 共识问题涉及最多的主题为结局(64%)、适应证(49%)和特定患者人群(38%)。
  • 跨小组问题经归纳排序后形成21个优先研究问题。
  • 作者认为这些关键主题应在未来创伤氨甲环酸研究的资助中优先考虑。

适用人群与场景

  • 创伤性出血和创伤性脑损伤患者(原文提及氨甲环酸用于 traumatic hemorrhage 和 traumatic brain injury)。

研究设计与关键结果

  • 研究类型:基于德尔菲法的共识研究问题二次分析;数据来源为11个NTRAP专题小组收集的共识研究优先问题数据库。
  • 检索关键词为「tranexamic」和「TXA」,7个小组共提出73个氨甲环酸相关问题,其中46个达成共识。
  • 问题涉及主题的占比:结局64%、适应证49%、特定患者人群38%。
  • 因跨小组重叠,问题经归纳排序后形成21个优先研究问题。

证据类型、等级与局限

  • 证据类型:德尔菲法共识研究问题的二次分析;证据等级:预后与流行病学;Level V。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Tranexamic acid (TXA) is an antifibrinolytic drug that is used in traumatic hemorrhage and traumatic brain injury. Although TXA is considered relatively safe and inexpensive and is widely available, data regarding its mechanisms, optimal dosing, and timing, as well as relative risks and benefits for different patient populations, are inconsistent. In this study, we aim to identify and summarize consensus research questions related to TXA across all National Trauma Research Action Plan (NTRAP) Delphi expert panels to identify priorities for future research on TXA in trauma.

METHODS: A secondary analysis was performed using consensus-based research priorities collected by 11 NTRAP topic panels using a Delphi methodology. The database of questions was queried for the keywords "tranexamic" and "TXA." The identified questions were sorted by subject matter and summarized.

RESULTS: Seven panels included a total of 73 TXA-related questions. Forty-six questions reached consensus. The most addressed topic was outcomes (discussed in 64% of questions) followed by indications (49%) and specific patient populations (38%). Because of overlap across panels, questions were summarized and sorted by topic resulting in 21 priority research questions.

CONCLUSION: Seventy-three total questions and 46 questions reaching consensus were identified by NTRAP panelists. The key topics identified in these questions should be prioritized in future funded research on TXA in trauma.

LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level V.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Brito AM, Meizoso JP, Costantini TW, et al. Research priorities in tranexamic acid after trauma: Secondary analysis of the National Trauma Research Action Plan. J Trauma Acute Care Surg. 2024. PMID: 38689399. doi:10.1097/TA.0000000000004358

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。